What is it about?
This chapter presents the results of the author’s previously unpublished study of 39 therapy-resistant pemphigus patients who then received rituximab treatment in Razi Hospital, Tehran, Iran, from 2008 to 2012. The maximum time interval between the last dosage of rituximab and follow-up was 1 month.
Featured Image
Read the Original
This page is a summary of: Research Results, November 2017, Springer Science + Business Media,
DOI: 10.1007/978-3-319-67759-0_20.
You can read the full text:
Contributors
The following have contributed to this page
